Nasdaq

Of the 32 companies in the index, 14 firms saw their stock prices increase, while 18 saw their share prices decline.

The firm offered 15,870,000 shares of its common stock, including 2,070,000 shares sold pursuant to the full exercise of the underwriters' option.

The notice was issued due to the company's extended period of non-compliance with the minimum $2.5 million stockholder's equity requirement for continued listing.

Of the 32 companies in the index, 27 firms saw their stock prices increase, while 5 saw their share prices decline.

The company, which is developing instrument-free, low-cost molecular diagnostics platform for infectious disease testing, plans to float its shares on the Nasdaq.

Growth was driven by demand in its life science segment, particularly for COVID-19-related products, while the diagnostics segment saw uneven improvement.

Not every company in the 360Dx Index had significant gains, but multiple companies saw their share prices double. 

Of the 32 companies in the index, 21 firms saw their stock prices increase, while 11 firms' share prices decreased. 

Quidel and Accelerate Diagnostics had the biggest declines in their share prices as the Index lagged behind the broader markets.

Of the 32 companies in the index, 14 firms saw their stock prices increase, while 18 firms' share prices decreased.